


WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising about 25 to 70 % by weight of the active ingredient of structural formula I



or a pharmaceutically acceptable salt thereof;
about 25 to 70 % by weight of mannitol or about 25 to 70 % by weight of a mixture of mannitol and microcrystalline cellulose;
about 1 to 5 % by weight of a disintegrant;
about 0 to 5 % by weight of a binding agent; and
about 1 to 3 % by weight of a lubricant.

2. The pharmaceutical composition of Claim 1 wherein said disintegrant is croscarmellose sodium, said binding agent is hydroxypropylcellulose, and said lubricant is magnesium stearate.

3. The pharmaceutical composition of Claim 2 comprising about 33 to 67 % by weight of said active ingredient;
about 25 to 60 % by weight of mannitol;
about 1 to 4 % by weight of croscarmellose sodium;
about 1 to 4 % by weight of hydroxypropylcellulose; and
about 1 to 2 % by weight of magnesium stearate.

4. The pharmaceutical composition of Claim 3 comprising about 33 to 67 % by weight of said active ingredient;
about 25 to 60 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;

about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

5 5. The pharmaceutical composition of Claim 1 additionally
comprising about 0 to 0.2 % by weight of an antioxidant.

6. The pharmaceutical composition of Claim 5 wherein said
antioxidant is BHT or BHA.

10 7. The pharmaceutical composition of Claim 2 comprising
about 33 % by weight of said active ingredient;
about 60 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and
15 about 2 % by weight of magnesium stearate.

8. The pharmaceutical composition of Claim 7 additionally
comprising about 0.02 % by weight of BHT or BHA.

20 9. The pharmaceutical composition of Claim 2 comprising
about 33 % by weight of said active ingredient;
about 40 % by weight of mannitol;
about 20 % by weight of microcrystalline cellulose;
about 3 % by weight of croscarmellose sodium;
25 about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

10. The pharmaceutical composition of Claim 9 additionally
comprising about 0.02 % by weight of BHT or BHA.

30 11. The pharmaceutical composition of Claim 2 comprising
about 50 % by weight of said active ingredient;
about 40 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
35 about 3 % by weight of hydroxypropylcellulose; and

about 2 % by weight of magnesium stearate.


12. The pharmaceutical composition of Claim 11 additionally comprising about 0.02 to 0.03 % by weight of BHT or BHA.

13. The pharmaceutical composition of Claim 2 comprising about 67 % by weight of said active ingredient;
about 25 % by weight of mannitol;
about 3 % by weight of croscarmellose sodium;
about 3 % by weight of hydroxypropylcellulose; and
about 2 % by weight of magnesium stearate.

14. The pharmaceutical composition of Claim 13 additionally comprising about 0.02 % by weight of BHT or BHA.

15. The pharmaceutical composition of Claim 1 prepared by wet granulation methods.

16. A pharmaceutical composition comprising about 33 to 67 % by weight of the active ingredient of structural formula I



or a pharmaceutically acceptable salt thereof;
about 25 to 60 % by weight of mannitol ;
about 0 to 20 % by weight of microcrystalline cellulose;
about 1 to 5 % by weight of a disintegrant;
about 0 to 5 % by weight of a binding agent; and
about 1 to 3 % by weight of a lubricant.

17. The pharmaceutical composition of Claim 16 wherein said disintegrant is croscarmellose sodium, said binding agent is hydroxypropylcellulose, and said lubricant is magnesium stearate.

5

18. The pharmaceutical composition of Claim 17 comprising about 33 to 67 % by weight of said active ingredient; about 25 to 60 % by weight of mannitol; about 3 % by weight of croscarmellose sodium; about 3 % by weight of hydroxypropylcellulose; and about 2 % by weight of magnesium stearate.

10

19. The pharmaceutical composition of Claim 16 prepared by direct compression methods.

15

20. A method of inhibiting bone resorption in a human in need thereof comprising orally administering to said human a bone resorption-inhibitory amount of the pharmaceutical composition of Claim 1.

20

21. A method of treating osteoporosis in a human in need thereof comprising orally administering to said human a therapeutically effective amount of the pharmaceutical composition of Claim 1.

25

22. The pharmaceutical composition of Claim 1 further comprising one or more agents selected from the group consisting of flavoring agents, colorants, and sweeteners.

30